Singular Genomics Systems, Inc. (NASDAQ: OMIC) is a life science technology company specializing in the development and commercialization of advanced genomic and multi-omics sequencing solutions. The company’s flagship offering, the G4™ System, integrates proprietary sequencing chemistry, high-throughput optics, and bioinformatics software to deliver rapid, scalable, and cost-effective analyses of DNA, RNA, and epigenetic modifications. Singular Genomics also provides a range of reagents, consumables, and cloud-based data analysis tools designed to support applications in research genomics, clinical discovery, and pharmaceutical development.
Founded in 2016 as a spin-out from pioneering research in single-molecule sequencing, Singular Genomics has built a platform aimed at addressing key challenges in accuracy, speed, and flexibility. Early investments were directed toward refining sequencing-by-synthesis chemistry and developing an open software architecture that allows for seamless integration with existing laboratory workflows. Since launching its first commercial instruments in 2021, the company has expanded its customer base across academic institutions and industrial research laboratories.
Headquartered in San Diego, California, Singular Genomics serves a global market that includes North America, Europe, and select locations in the Asia-Pacific region. The company has established distribution partnerships and technical support centers to facilitate rapid deployment and training for users. Its technology has been applied to a wide array of projects, including population genetics studies, biomarker discovery, transcriptome profiling, and single-cell analyses, reflecting its commitment to enabling deeper insights across diverse fields of life sciences.
Singular Genomics’ leadership team combines deep expertise in molecular biology, engineering, and life sciences commercialization. The company was co-founded by Dr. Stephen Quake, a noted genomics researcher and Stanford University professor, who serves as chairman of the board. The executive team includes veterans of established sequencing and biotechnology firms, guiding product development, regulatory strategy, and global sales efforts. Together, they aim to drive innovation in multi-omics research and accelerate the adoption of next-generation sequencing technologies worldwide.
AI Generated. May Contain Errors.
Free OMIC Stock Alerts